
News|Videos|December 6, 2020
The Development and Treatment Potential of FTX-6058
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what FTX-6058 is, how it was developed, and what it is able to treat.
Advertisement
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham explains what FTX-6058 is, how it was developed, and what it is able to treat.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Apitegromab-mstn, First Muscle-Targeted SMA Therapy
2
Pharmacists Can Close the LDL Control Gap in Lipid Care
3
Predictive Models Could Address Missing Data in Advanced Prostate Cancer
4
Ivonescimab Significantly Extends OS Over Pembrolizumab in PD-L1-Positive Advanced NSCLC
5




































































































